Understanding Motor Neuron Disease (MND) & ALS: Symptoms, Causes & Support

MND / ALS Overview

Amyotrophic Lateral Sclerosis (ALS) is the most common adult-onset motor neuron disease (MND). Progressive degeneration of upper motor neurons (UMN: cortex → spinal cord) and lower motor neurons (LMN: anterior horn → muscle).

Epidemiology

  • Incidence: ~2/100,000/yr; prevalence ~5–7/100,000.
  • Peak onset: 55–75 years. <10% familial (fALS); 90% sporadic (sALS).
  • Male predominance (1.5:1) until age 70.

Clinical Presentation

Limb-Onset (~70%)

  • Asymmetric weakness, atrophy, fasciculations (LMN)
  • Spasticity, hyperreflexia, Babinski (UMN)
  • Foot drop, hand weakness, "split hand" (thenar wasting)

Bulbar-Onset (~25%)

  • Dysarthria (spastic/flaccid), dysphagia, tongue fasciculations, emotional lability (pseudobulbar affect)
  • Worse prognosis (median survival 2–3 yrs vs 3–5 yrs limb-onset)

Respiratory-Onset (Rare)

Orthopnea, morning headache, fatigue — diaphragm weakness.

Genetics

  • C9orf72 hexanucleotide repeat — 40% fALS, 7% sALS (also FTD).
  • SOD1 — 12% fALS.
  • TARDBP, FUS, NEK1, KIF5A, TBK1 — others.
  • Genetic testing recommended for all (informs prognosis, family counseling, trial eligibility).

Diagnosis

El Escorial / Gold Coast criteria: UMN + LMN signs in multiple regions, progression, exclusion of mimics (MMN, CIDP, cervical myelopathy, Kennedy's disease, inclusion body myositis). EMG/NCS essential.

Management (Multidisciplinary Clinic Extends Survival & QoL)

  • Riluzole (oral) — modest survival benefit (2–3 mo).
  • Edaravone (IV/oral) — slows functional decline in subset.
  • Tofersen (ASO for SOD1) — approved 2023.
  • NIV (BiPAP) — extends survival 6–12 mo, improves QoL.
  • Gastrostomy (PEG) — nutrition, hydration.
  • PT/OT/SLP, AAC (eye-gaze), palliative care early.

Research Horizons

Gene therapy (C9orf72 ASO), stem cells, biomarkers (NfL, pNfH), neuromodulation, AI-driven clinical trial matching.

Genetic Disorders - Related Articles